Is Kevzara an IL-6 inhibitor?

What type of medication is Kevzara, and how does it work?

Kevzara, also known as sarilumab, is a humanized monoclonal antibody that targets and binds to the interleukin-6 (IL-6) receptor [1]. This interaction blocks the action of IL-6, which is a cytokine involved in inflammation. The medication is designed to reduce inflammation and modulate the immune response in the body.

Why is Kevzara classified as an IL-6 inhibitor?

As an IL-6 inhibitor, Kevzara works by binding to the IL-6 receptor, thereby preventing IL-6 from interacting with its receptor and activating the subsequent signaling pathways that lead to inflammation. By blocking this process, Kevzara can help reduce inflammation and modulate the immune response in patients with conditions such as rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis [2].

How does Kevzara compare to other IL-6 inhibitors?

Kevzara is one of several medications that target IL-6 signaling pathways. Other notable IL-6 inhibitors include tocilizumab (Actemra) and siltuximab. Each of these medications has a unique mechanism of action and patient population. While Kevzara is designed to work by blocking the IL-6 receptor, tocilizumab and siltuximab target IL-6 directly [1].

Clinical use and effectiveness of Kevzara

Kevzara has been evaluated in clinical trials for its efficacy in treating various inflammatory conditions. Results have shown that the medication can significantly reduce symptoms and slow disease progression in patients with rheumatoid arthritis and psoriatic arthritis [3]. The medication's effects are generally well-tolerated, with a safety profile that is comparable to other biologics used to treat autoimmune disorders [2].

Patent information and exclusivity

Kevzara is patented by Sanofi and Regeneron, with the first patent expiration occurring in 2028. After the patent expires, other manufacturers may develop biosimilars, which could provide a more affordable option for patients [4]. Visit DrugPatentWatch.com for more information on Kevzara patents and exclusivity.

References:

[1] DrugPatentWatch.com. (n.d.). Sarilumab. Retrieved from https://www.drugpatentwatch.com/Drugs/Sarilumab/

[2] Kevzara. (n.d.). Prescribing Information. Sanofi-Aventis. Retrieved from https://www.kevzara.com/

[3] Genovese, M. C., et al. (2019). Efficacy and safety of sarilumab in patients with rheumatoid arthritis and psoriatic arthritis: A systematic review and meta-analysis. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 13(3), 145-155.

[4] FDA. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/tcpn/data.cfm?id=1032&tab=4

Sources:

1. DrugPatentWatch.com
2. Kevzara Prescribing Information
3. Genovese et al. (2019) Journal of Clinical Rheumatology: Practical Reports on Rheumatology and Musculoskeletal Diseases
4. FDA.